Form 8-K DEXCOM INC For: Oct 24
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
DexCom (DXCM) PT Raised to $86 at Bernstein SocGen Group
October 25, 2024 6:25 AM EDTBernstein SocGen Group analyst Lee Hambright raised the price target on DexCom (NASDAQ: DXCM) to $86.00 (from $82.00) while maintaining a Market Perform rating.
The analyst comments "In-line quarter. Revenue grew 3% organic, landing at the high-end of the reduced guidance range that DXCM set on the Q2 call (1% to 3%). U.S. sales declined -2% organic,... More
BTIG Reiterates Buy Rating on DexCom (DXCM)
October 25, 2024 5:23 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $120.00 price target on DexCom (NASDAQ: DXCM).
The analyst comments "Dexcom reported $994.2M in Q3 revenue (+2% y/y rep., +3% y/y org.), $4M above the consensus estimate of $990M. Q3 adj. EPS was $0.45, two cents above consensus. DXCM missed Visible Alpha consensus' U.S. sales expectation by $19M, reporting $701.9M (-2% y/y) and beat by $22M on OUS sales of $292.3M (+12% y/y rep.). Despite the light U.S. result, management commentary was upbeat, highlighting a record level of new patient starts, progress and momentum on... More



